Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention

PHASE2TerminatedINTERVENTIONAL
Enrollment

466

Participants

Timeline

Start Date

October 19, 2021

Primary Completion Date

July 31, 2024

Study Completion Date

August 30, 2024

Conditions
Migraine
Interventions
DRUG

ABP-450

ABP-450 (prabotulinumtoxinA) contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.

Trial Locations (55)

2170

Liverpool Hospital, Liverpool

3004

Alfred Hospital, Melbourne

3124

Emeritus Research, Camberwell

14221

Upstate Clinical Research Associates LLC, Williamsville

14226

Dent Neurologic Institute, Amherst

15236

Preferred Primary Care Physicians, Pittsburgh

19107

Thomas Jefferson University, Jefferson Headache Center, Philadelphia

30060

Drug Studies America, Inc, Marietta

30328

NeuroTrials Research Inc. - Clinedge - PPDS, Atlanta

32746

Sandhill Research, LLC, Lake Mary

33016

Quality Research of South Florida, Hialeah

33126

BioMed Research Institute, INC, Miami

33157

Innovation Medical Research Center, Palmetto Bay

33467

Canvas Clinical Research, Lake Worth

33810

Clinical Research of Central Florida - ClinEdge - PPDS, Winter Haven

34470

Renstar Medical Research, Ocala

37203

Bryant Research Group, Nashville

37421

WR-ClinSearch, Chattanooga

40825

Quest Research Institute - Hunt - PPDS, Farmington Hills

43016

Centricity Research Dublin Multispecialty, Dublin

43054

The Orthopedic Foundation, New Albany

45432

META Medical Research Institute, LLC, Dayton

60607

Cedar Crosse Research Center, Chicago

63303

StudyMetrix Research, LLC, City of Saint Peters

65810

Clinvest Research LLC, Springfield

66211

Kansas Institute of Research, LLC, Overland Park

68114

Quality Clinical Research, Omaha

68128

Barrett Clinic, P.C. - Clinedge - PPDS, La Vista

70043

Crescent City Headache and Neurology Center, Chalmette

70072

Legacy Clinical Solutions: Tandem Clinical Research, LLC - Clinedge - PPDS, Marrero

75225

Alina Clinical Trials, Dallas

77478

Houston Neurology Associates, Sugar Land

80033

Paradigm Clinical Research Centers, Wheat Ridge

80918

Delta Waves LLC - Hunt - PPDS, Colorado Springs

83642

Velocity Clinical Research - Boise - ERN - PPDS, Meridian

84058

Aspen Clinical Research LLC - Clinedge - PPDS, Orem

85018

Elite Clinical Studies, LLC, Phoenix

85032

Arizona Neuroscience Research, Phoenix

85226

MDFirst Research, Chandler

85281

Clinical Research Consortium Arizona, Tempe

87102

Albuquerque Clinical Trials Inc - Clinedge - PPDS, Albuquerque

89104

Wake Research - CRCN, LLC, Las Vegas

90067

Los Angeles Headache Center, Los Angeles

91942

Velocity Research San Diego, La Mesa

92103

Artemis Institute For Clinical Research LLC - San Diego - ClinEdge - PPDS, San Diego

92324

Axiom Research LLC, Colton

92374

Anderson Clinical Research, Redlands

98004

Northwest Clinical Research Center, Bellevue

06905

New England Institute for Neurology and Headache, Stamford

02131

Boston Clinical Trials Inc, Boston

02451

MedVadis Research, Waltham

T4P 1K4

CARe Clinic, Red Deer

B3S 1N2

True North Clinical Research, Halifax

N7T 4X3

Bluewater Clinical Research Group, Sarnia

G1N 4V3

Diex Recherche Québec, Québec

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

PPD Development, LP

INDUSTRY

lead

AEON Biopharma, Inc.

INDUSTRY

NCT05016661 - Extension Study of ABP-20001 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 for Migraine Prevention | Biotech Hunter | Biotech Hunter